Quest Diagnostics Incorporated (NYSE:DGX), a leader in diagnostic information services, has reached a new 52-week high, with its stock price soaring to $155.5. This milestone reflects a significant uptrend in the company's market performance, marking a notable achievement for shareholders and potential investors. Over the past year, Quest Diagnostics has witnessed a robust 1-year change, with an impressive 15.43% increase in its stock value. This growth underscores the company's strong financial health and the positive reception of its strategic initiatives in the competitive healthcare landscape. Investors are closely monitoring Quest Diagnostics as it continues to innovate and expand its services, further solidifying its position in the industry.
In other recent news, Quest Diagnostics saw a 2.5% increase in total revenue for Q2 2024, reaching $2.99 billion. The company's full-year 2024 financial guidance anticipates revenues between $9.5 billion and $9.58 billion. Quest Diagnostics completed the acquisition of LifeLabs, expected to generate approximately $710 million in annual revenues. The company is set to acquire select assets of the outreach laboratory services business from University Hospitals, Ohio, anticipated to finalize in Q4 2024.
Evercore ISI resumed its coverage on Quest Diagnostics, assigning an In Line rating, and establishing a price target of $165.00. The firm projects modest accretion from the LifeLabs deal and anticipates contributions from the University Hospitals Outreach acquisition. Evercore ISI forecasts the base business will grow at a mid-single-digit rate and points to slight margin expansion due to factors such as reduced impact from COVID and a stable labor environment.
Mizuho maintained an Outperform rating on Quest Diagnostics and raised the price target to $160 from $155. Furthermore, Quest Diagnostics announced a global collaboration with BD (Becton, Dickinson and Company) to develop flow cytometry-based companion diagnostics, aiming to enhance treatment selection for cancer patients and those with other diseases. These are some of the recent developments in Quest Diagnostics' operations.
InvestingPro Insights
Quest Diagnostics (DGX) has not only hit a new 52-week high but also exhibits several financial strengths that might interest investors. According to InvestingPro data, the company boasts a market capitalization of $17.3 billion and maintains a price-to-earnings (P/E) ratio of 20.71, which adjusts to a slightly lower 19.32 when considering the last twelve months as of Q2 2024. This could indicate the stock is trading at a premium relative to its near-term earnings growth, a point that investors might weigh against the company's consistent performance.
From a profitability standpoint, Quest Diagnostics has shown resilience, remaining profitable over the last twelve months. InvestingPro Tips highlight that the management's confidence is reflected in their aggressive share buyback strategy and that the company has not only raised its dividend for 13 consecutive years but has also maintained dividend payments for 21 consecutive years, with a current dividend yield of 1.94%.
The company's stock has experienced a significant price uptick over the last six months, with a 25.39% total return. This aligns with the company's trading near its 52-week high, at 99.58% of this peak value. For those considering long-term investment, Quest Diagnostics' commitment to shareholder returns and its stable stock performance, as indicated by low price volatility, might be particularly appealing. For a deeper dive into Quest Diagnostics' financials and additional InvestingPro Tips, investors can explore further at https://www.investing.com/pro/DGX, where several other tips are available to provide a comprehensive view of the company's prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.